ZyVersa Therapeutics Investor Relations Material
Latest events
AGM 2023
ZyVersa Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from ZyVersa Therapeutics Inc
Access all reports
ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company dedicated to developing innovative drugs for renal and inflammatory diseases with significant unmet medical needs. The company leverages advanced proprietary technologies to create first-in-class therapeutics. Its key product candidates include the Cholesterol Efflux Mediator VAR 200, which is being developed to remove excess cholesterol from the kidneys' filtration system to prevent damage and reduce proteinuria, potentially treating conditions like diabetic kidney disease, focal segmental glomerulosclerosis (FSGS), and Alport syndrome. Another major candidate is the Inflammasome ASC Inhibitor IC 100, a monoclonal antibody designed to inhibit inflammation by targeting the ASC protein, which is implicated in a variety of inflammatory conditions, including neuroinflammatory diseases like Parkinson’s and Alzheimer’s, as well as metabolic complications related to obesity. The company is headquartered in Weston, Florida, and its shares are listed on the NASDAQ.
Latest articles
The Samsung Co-CEOs: Jong-Hee Han & Young-Hyun Jun
Samsung Electronics' dual-CEO structure, led by Jong-Hee Han and Young-Hyun Jun, is designed to navigate the complexities of its diverse business.
3 Oct 2024
Irwin Jacobs & Andrew Viterbi: Qualcomm's Pioneering Founders
In 1985, Irwin Jacobs and Andrew Viterbi co-founded Qualcomm, a leading company in telecommunications and semiconductor innovation.
3 Oct 2024
AMD: Shaping the Future of Semiconductor Processors
With a background in the U.S. semiconductor evolution, AMD has grown into a powerful player in producing high-quality, competitive processors.
1 Oct 2024
Ticker symbol
ZVSA
Country
🇺🇸 United States